Benzoimidazole compound containing amide and application thereof

A technology of benzimidazole and compound, applied in the field of T-LAK cell-derived protein kinase inhibitor

Active Publication Date: 2019-07-12
SHENYANG PHARMA UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, TOPK has become a new target for tumor treatment, and there is no drug specifically targeting this target on th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzoimidazole compound containing amide and application thereof
  • Benzoimidazole compound containing amide and application thereof
  • Benzoimidazole compound containing amide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0059] The schemes outline the preparative steps used to prepare the compounds of the invention.

[0060]

[0061] process

[0062] Among them, R 1 , R 2 , R 3 , R 5 as mentioned earlier.

[0063] The present invention is described in detail with the following examples. However, it should be understood that the present invention is not limited to the specific recited examples below.

Embodiment 1

[0064] Example 1: 2-{3-{{2-{[(1H-benzimidazol-2-yl)thio]methyl}-3-methylpyridin-4-yl}oxy}propoxy} -Preparation of N-cyclohexylacetamide (compound X01)

[0065] Step A: Preparation of 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylthio}-1H-benzimidazole

[0066] 2-Chloromethyl-4-(3-methoxypropoxy)-3-picoline hydrochloride (0.50g, 1.88mmol) was placed in a 125ml eggplant-shaped bottle, and 11ml of ethanol was added to dissolve it, Then 1H-benzimidazole-2-thiol (0.28g, 1.88mmol) and 4ml NaOH (80g / L) were added, refluxed at 68°C for 4h, and the reaction was complete as monitored by TLC. The reaction solution was poured into a 100ml beaker, cooled naturally to room temperature, a white solid was precipitated, and recrystallized from ethyl acetate and petroleum ether (2:1) to obtain 0.58 g of white needle-like crystals, with a yield of 89.3%. m.p.: 115-118°C (literature value: 116-118°C).

[0067] Step B: Preparation of 3-{{2-{[(1H-benzimidazol-2-yl)thio]methyl}-3-methylpyri...

Embodiment 2

[0071] Example 2: 2-{3-{{2-{[(1H-benzimidazol-2-yl)thio]methyl}-3-methylpyridin-4-yl}oxy}propoxy} -Preparation of N-isopropylacetamide (compound X02)

[0072] Referring to the preparation method of Example 1, 0.57 g of white solid was obtained with a yield of 87.2%. m.p.: 162.9-164.7℃; IR: (KBr,cm -1 )3278,3086,2924,1656,1584,1464,1442,1369,732; 1 H-NMR (400MHz, DMSO): δ8.36(d, 1H, J=7.4Hz, Pyridine-6-H), 8.22(d, 1H, J=5.6Hz, Ar-H), 7.63~7.45(m ,1H,Ar-H),7.44~7.37(m,1H,Ar-H),7.21~7.13(m,2H,Pyridine-5-H,N-H),6.96(d,1H,J=5.7Hz,Ar -H),4.78(s,2H,SCH 2 ),4.69(s,2H,OCH 2 ), 4.12(t, J=6.2Hz, 2H, CH 2 ),3.82(dq,J=13.5,6.7Hz,1H,NCH),3.57(dd,J=10.5,5.7Hz,2H,CH 2 ),2.20(s,3H),1.89(p,J=6.1Hz,2H),1.08(s,3H),1.08(s,3H),1.07(s,3H); ESI-MS(m / z) :429.3([M+H] + ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine, and relates to a 2-[(pyridin-2-yl-methyl)thio]-1H-benzimidazole compound and a preparation method and application thereof. The formula of the2-[(pyridin-2-yl-methyl)thio]-1H-benzimidazole compound and a pharmaceutically acceptable salt is as follows: R1 and R2 are the same or different, and are selected from hydrogen, C1-C8 alkyl, C3-C6 cycloalkyl, phenyl, halogen substituted phenyl, C1-C4 alkyl substituted phenyl, C1-C4 alkoxy substituted phenyl, halogen and C1-C4 alkyl simultaneously substituted phenyl, halogen and C1-C4 alkoxy simultaneously substituted phenyl, halogen-substituted C1-C4 alkyl substituted phenyl, benzyl, and 4-benzyloxyphenyl; or R1, R2 and the nitrogen atom connected with them constitutes a substituted or un-substituted morpholinyl, phenylpiperazine or diphenylmethylpiperazine; the substituent is C1-C4 alkoxy, C1-C4 alkyl and halogen; and R3 and R5 can be selected from hydrogen and C1-C4 alkyl. The compoundhas a simple synthesis method, is suitable for industrialized production, and has obvious anti-tumor activity.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to 1-aryl-3-{4-[(pyridin-2-ylmethyl)thio]phenyl}urea compounds and a preparation method thereof, and also relates to its function as BRaf kinase, vascular Endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (Platelet-derived growth factor receptors-β, PDGFR-β) and T-LAK cell-derived protein kinase (T-LAK cell-originated protein kinase, TOPK) inhibitor application. Background technique [0002] In recent years, with the continuous elucidation of tumor pathogenesis and the continuous discovery of anti-tumor targets, multi-target inhibition of tumor signal transduction has become an important direction for the development of tumor drugs. Compared with single-target drugs and multiple single-target drugs in combination, multi-target drugs have more advantages: drug interactions can be avoided, adverse reactions can be reduced, and the therapeutic ef...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D401/12A61K31/4439A61K31/496A61K31/5377A61P35/00
CPCC07D401/12A61P35/00
Inventor 胡春孙胜男张传明李永鹏孙媛媛秦凤云王琳
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products